💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Teplizumab

CHEMBL1743078 Phase 4 Одобрено Antibody
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Teplizumab is a humanized anti-CD3 monoclonal antibody that binds to the CD3 epsilon chain of the T-cell receptor complex, inducing partial agonism and selectively modulating autoreactive T cells responsible for pancreatic beta-cell destruction in type 1 diabetes. It is approved to delay the onset of stage 3 type 1 diabetes in at-risk individuals aged 8 years and older, representing the first disease-modifying therapy for type 1 diabetes prevention. By shifting the balance from effector to regulatory T cells, it preserves residual beta-cell function.

Терапевтические области

Psoriasis Type 2 Diabetes

Механизм действия

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Teplizumab is a humanized anti-CD3 monoclonal antibody that binds to the CD3 epsilon chain of the T-cell receptor complex, inducing partial agonism and selectively modulating autoreactive T cells responsible for pancreatic beta-cell destruction in type 1 diabetes. It is approved to delay the onset of stage 3 type 1 diabetes in at-risk individuals aged 8 years and older, representing the first disease-modifying therapy for type 1 diabetes prevention. By shifting the balance from effector to regulatory T cells, it preserves …

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Teplizumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1743078. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.